全文获取类型
收费全文 | 3213篇 |
免费 | 405篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 117篇 |
儿科学 | 179篇 |
妇产科学 | 163篇 |
基础医学 | 292篇 |
口腔科学 | 63篇 |
临床医学 | 303篇 |
内科学 | 577篇 |
皮肤病学 | 98篇 |
神经病学 | 52篇 |
特种医学 | 87篇 |
外国民族医学 | 3篇 |
外科学 | 578篇 |
综合类 | 192篇 |
预防医学 | 60篇 |
眼科学 | 37篇 |
药学 | 67篇 |
中国医学 | 9篇 |
肿瘤学 | 800篇 |
出版年
2024年 | 9篇 |
2023年 | 64篇 |
2022年 | 108篇 |
2021年 | 162篇 |
2020年 | 160篇 |
2019年 | 167篇 |
2018年 | 135篇 |
2017年 | 158篇 |
2016年 | 163篇 |
2015年 | 150篇 |
2014年 | 189篇 |
2013年 | 232篇 |
2012年 | 159篇 |
2011年 | 147篇 |
2010年 | 130篇 |
2009年 | 136篇 |
2008年 | 136篇 |
2007年 | 151篇 |
2006年 | 143篇 |
2005年 | 116篇 |
2004年 | 106篇 |
2003年 | 72篇 |
2002年 | 56篇 |
2001年 | 65篇 |
2000年 | 47篇 |
1999年 | 36篇 |
1998年 | 57篇 |
1997年 | 50篇 |
1996年 | 32篇 |
1995年 | 39篇 |
1994年 | 27篇 |
1993年 | 27篇 |
1992年 | 28篇 |
1991年 | 32篇 |
1990年 | 15篇 |
1989年 | 20篇 |
1988年 | 21篇 |
1987年 | 16篇 |
1986年 | 24篇 |
1985年 | 14篇 |
1984年 | 11篇 |
1983年 | 9篇 |
1982年 | 8篇 |
1981年 | 18篇 |
1980年 | 10篇 |
1979年 | 9篇 |
1978年 | 4篇 |
1977年 | 6篇 |
1974年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有3677条查询结果,搜索用时 31 毫秒
51.
Satoshi Okayama M.D. Yoko Dote M.D. Yukiji Takeda M.D. Shiro Uemura M.D. Shinichi Fujimoto M.D. Ph.D. Yoshihiko Saito M.D. Ph.D. 《Echocardiography (Mount Kisco, N.Y.)》2013,30(1):E13-E15
A 63‐year‐old man was referred to our hospital because of a cardiac tumor. Transthoracic echocardiography revealed a rough, mobile tumor in the dilated right atrium, and transesophageal echocardiography showed that the tumor consisted of small, botryoidal masses. Catheter‐based biopsy carried a high risk of embolism. Therefore, we used F‐18‐fluorodeoxyglucose positron emission tomography (FDG‐PET), which revealed an abnormal accumulation in the right cervical lymph nodes, as well as in the heart. We safely performed biopsy of the lymph nodes and diagnosed the patient with primary cardiac lymphoma. We concluded that echocardiography and FDG‐PET are useful for selecting an appropriate biopsy site in primary cardiac lymphoma. 相似文献
52.
《Otolaryngologic clinics of North America》2016,49(4):1051-1065
53.
《Clinical colorectal cancer》2014,13(1):27-36
IntroductionThis prospective study assessed the safety and outcomes of selective internal radiation therapy (SIRT) using yttrium-90 (90Y) resin microspheres as a salvage therapy for liver-predominant metastases of colorectal cancer in patients with documented progression after hepatic arterial chemotherapy (HAC) and systemic chemotherapy.Patients and MethodsWe recruited 19 patients who had received a mean of 2.9 prior lines of chemotherapy and ≥ 1 line of HAC. Dose-limiting toxicities (grade 3 or higher) were catalogued using Common Terminology Criteria for Adverse Events version 3.0. At 4 to 8 weeks and 3 to 4 months post SIRT, responses were assessed by carcinoembryonic antigen (CEA), and quantitative imaging using Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST). Liver progression-free survival (LPFS), progression-free survival (PFS), and overall survival (OS) were calculated using Kaplan-Meier methodology.ResultsMedian follow-up was 31.2 months after SIRT. Within 6 weeks of SIRT, 3 patients (15.8%) experienced grade 3 toxicity. There was no incidence of radiation-induced liver disease. Responses by RECIST, PERCIST, and CEA were, respectively, 0%, 20%, and 32% at 4 to 8 weeks and 5%, 33%, and 21% at 3 to 4 months post SIRT; 53% of patients had stable disease (by RECIST) at 3 to 4 months. Of 19 patients, 4 (21.1%) had liver ablation, 9 (47%) received additional HAC, and 17 (89%) received systemic chemotherapy after SIRT. Median LPFS, PFS, and OS after SIRT were 5.2 months, 2.0 months, and 14.9 months, respectively.ConclusionSIRT was well tolerated and did not prohibit subsequent treatment, resulting in a median OS of 14.9 months in this heavily pretreated population. 相似文献
54.
55.
Andrew R. Lavik Fei Zhong Ming-Jin Chang Edward Greenberg Yuvraj Choudhary Mitchell R. Smith Karen S. McColl John Pink Frederic J. Reu Shigemi Matsuyama Clark W. Distelhorst 《Oncotarget》2015,6(29):27388-27402
Bcl-2 inhibits apoptosis by two distinct mechanisms but only one is targeted to treat Bcl-2-positive malignancies. In this mechanism, the BH1-3 domains of Bcl-2 form a hydrophobic pocket, binding and inhibiting pro-apoptotic proteins, including Bim. In the other mechanism, the BH4 domain mediates interaction of Bcl-2 with inositol 1,4, 5-trisphosphate receptors (IP3Rs), inhibiting pro-apoptotic Ca2+ signals. The current anti-Bcl-2 agents, ABT-263 (Navitoclax) and ABT-199 (Venetoclax), induce apoptosis by displacing pro-apoptotic proteins from the hydrophobic pocket, but do not inhibit Bcl-2-IP3R interaction. Therefore, to target this interaction we developed BIRD-2 (Bcl-2 IP3 Receptor Disruptor-2), a decoy peptide that binds to the BH4 domain, blocking Bcl-2-IP3R interaction and thus inducing Ca2+-mediated apoptosis in chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma cells, including cells resistant to ABT-263, ABT-199, or the Bruton’s tyrosine kinase inhibitor Ibrutinib. Moreover, combining BIRD-2 with ABT-263 or ABT-199 enhances apoptosis induction compared to single agent treatment. Overall, these findings provide strong rationale for developing novel therapeutic agents that mimic the action of BIRD-2 in targeting the BH4 domain of Bcl-2 and disrupting Bcl-2-IP3R interaction. 相似文献
56.
Gary B. Deutsch Sandeep Anantha Sathyanarayana Jeffrey Nicastro Ernesto Molmenti Gene Coppa Eugene Rubach Barak Friedman 《The International journal of angiology》2012,21(3):155-158
Meckel diverticula are remnants of the omphalomesenteric duct. They have 2% incidence in the general population, are usually asymptomatic, and tend to be diagnosed incidentally. The generally held principle had been that asymptomatic cases do not require resection, as exemplified by a 2008 systematic review of over 200 studies. However, a recent series reported an increased risk of malignancies, and recommended mandatory resection. We present a case of Meckel diverticulitis with concurrent infiltrative appendiceal carcinoid in a patient with right lower quadrant pain. 相似文献
57.
58.
MicroRNAs (miRNAs) have become one of the hottest topics in biology over recent years, but remarkably have only been formally recognized for just over 10 years. These endogenously produced short (19–24 nt) non-coding RNAs have introduced an entirely new paradigm in our understanding of gene control and it is now evident that miRNAs play a crucial regulatory role in many, if not all, physiological and pathological processes. In this review we provide an overview of the role and potential clinical utility for miRNAs in hematological malignancies and their function in normal hematopoiesis. Although still in its infancy, the miRNA field has already added much to our understanding of hematological processes, and provides us with novel tools as both biomarkers and therapeutic agents for hematological malignancies. 相似文献
59.
60.